Presenter Profile: Isaac Joseph, MPH
Epidemiologist, Data/Research Scientist, and Patient Advocate
Move Against Cancer Africa, Nigeria
ILCN: What is your presentation about?
My presentation is centered on empowering change and amplifying impact through research advocacy activities with focus on comparative perspectives on research advocacy in Nigeria. It highlights the importance of research advocacy in lung cancer, the challenges and opportunities in the Nigerian context, and the initiatives and impacts from Move Against Cancer Africa.
ILCN: Why is this topic timely or important in 2024?
This is due to the increasing prevalence of lung cancer globally and the need for effective advocacy to improve the aftereffects on patients. The constantly changing and evolving landscape of lung cancer treatment, including the integration of molecular testing and personalized medicine, requires robust research advocacy to ensure accessibility and affordability for all patients, particularly those in resource-limited settings like Nigeria. Very important also is the growing awareness and increase of cases of non-smoking-related lung cancer. This underscores the need for comprehensive risk factor identification, education as well as early detection strategies.
10:45-12:00 PDT, Sunday, September 8
Room 30A, San Diego Convention Center
Empowering Change and Amplifying Impact Through Research Advocacy Activities: Comparative Perspectives on Research Advocacy in Nigeria
During a Joint IASLC & GLCC Session, Isaac Joseph, MPH, will be joined by other experts from North American, Europe, and Australia to discuss the importance of patient advocacy efforts.
ILCN: How did you become involved with this area of lung cancer research, care, or advocacy?
My involvement with lung cancer research and advocacy began through my work with Move Against Cancer Africa (MACA), where I lead data collection and analysis initiatives to support cancer advocacy and awareness campaigns. My constant communication with patients helped me develop passion and dedication to help them navigate getting timely care. Additionally, I was privileged to win the IASLC Patient Advocate Award in 2023, which further solidified my commitment.
ILCN: What are you most looking forward to during the 50th Anniversary World Conference on Lung Cancer?
Engaging with global experts and stakeholders in lung cancer research and advocacy, sharing initiatives and success stories with caregivers and survivors as well as establishing collaborations that can improve lung cancer advocacy and patient outcomes in Nigeria, Africa, and beyond.
